NEW YORK – Precision therapy company Blueprint Medicines said on Wednesday that it had key updates for its RET-based oncology drug programs, including top-line data from the pralsetinib trial for patients with RET-mutant medullary thyroid cancer (MTC).
The top-line data from the Phase I/II ARROW trial will support a new drug application for pralsetinib that the company plans to file with the US Food and Drug Administration in the second quarter of 2020.